This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

NCT03780608 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Gastric Adenocarcinoma
Malignant Melanoma

Interventions

DRUG: AZD6738
DRUG: Durvalumab

Sponsor

Samsung Medical Center